Evidence map›Paper›PMID 29246956›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2018

Marshaling the Translational Potential of

Peter A Kanetsky, Jennifer L Hay

Open access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Increasing Skin Cancer Prevention in Young Adults: the Cumulative Impact of Personalized UV Photography and MC1R Genetic Testing.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023
    Trial
  2. Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Trial
  3. Trial
  4. Article
  5. Article
  6. An overview of benefits and risks of chronic melanocortin-1 receptor activation.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Review
  7. Article
  8. Article
  9. Interest and Utility ofJournal of skin cancer · 2022
    Article
  10. Article
  11. Article
  12. Germline mutations predisposing to melanoma.Journal of cutaneous pathology · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Peter A Kanetsky *Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, Florida. Peter.Kanetsky@Moffitt.org.
Jennifer L Hay *Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Personalized Genomic Testing for Melanoma: Maximizing Personal Utility and ReachR01CA181241 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERWICK, MARIANNE, HAY, JENNIFER L · 2014 to 2016
$2.1M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA181241
6 · The paper itself

Abstract

Melanoma rates have been increasing in the United States, and neither primary (sun protection and avoidance) nor secondary (skin examination) prevention is practiced consistently, even by those with melanoma risk factors. Inherited variation at

Indexed as

DNA Mutational AnalysisGenetic Predisposition to DiseaseGenetic TestingGenotypeHumansMelanomaMolecular Diagnostic TechniquesPrecision MedicinePrimary PreventionReceptor, Melanocortin, Type 1Risk AssessmentRisk FactorsSunlightTranslational Research, BiomedicalMC1R protein, humanReceptor, Melanocortin, Type 1

Identifiers

PMID29246956
PMCPMC5839988
OpenAlexW2773126211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.